ECTRIMS 2022 | The impact of comorbidities on treatment-related decisions in MS
Helen Tremlett, PhD, The University of British Columbia, Vancouver, Canada, discusses the impact of comorbidities on treatment-related decisions in multiple sclerosis (MS). The presence of comorbidities may delay the initiation of disease-modifying therapies as well as reduce treatment adherence. More evidence is needed to better guide appropriate therapeutic choices; however, many people with comorbidities are excluded from clinical trials, limiting the ability to acquire evidence to inform treatment decisions. This interview took place at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress 2022 in Amsterdam, The Netherlands.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Helen Tremlett has received research support in the last 3 years from the: Canada Research Chair Program, National MS Society, Canadian Institutes of Health Research, Canada Foundation for Innovation, MS Society of Canada, MS Scientific Research Foundation and the EDMUS Foundation (‘Fondation EDMUS contre la sclérose en plaques’).
